Physician profile
Zeba Ali
NPI 1962472159
$3,299.29
in general payments reported to CMS, 2019-2025
31 companies · $1,025 in 2025
The $1,025 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $209 · 2020: $16.69 · 2021: $195 · 2022: $258 · 2023: $552 · 2024: $1,043 · 2025: $1,025.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,620.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,620.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $660.69 | 2022-2025 | Vraylar, Linzess, Viberzi |
| Astrazeneca Pharmaceuticals Lp | $517.12 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Glaxosmithkline, LLC. | $254.60 | 2019-2024 | Trelegy Ellipta |
| Novo Nordisk INC | $236.02 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $174.23 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $147.38 | 2023-2025 | |
| Abbott Laboratories | $122.22 | 2021-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $118.87 | 2021-2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $115.63 | 2023-2025 | Cologuard Collection Kit |
| Vanda Pharmaceuticals INC. | $109.78 | 2025 | Fanapt |
| Amgen INC. | $109.49 | 2023-2025 | Otezla, Repatha, Otezla |
| Axsome Therapeutics, INC. | $83.82 | 2024-2025 | Auvelity |
| Shield Therapeutics INC | $77.84 | 2024 | |
| Xeris Pharmaceuticals, INC. | $69.90 | 2023-2025 | Gvoke Hypopen |
| Idorsia Pharmaceuticals US INC | $65.06 | 2023 | Quviviq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.25 | 2019-2024 | Synjardy, Jardiance, Tradjenta |
| Allergan, INC. | $48.72 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $42.58 | 2025 | Caplyta |
| Paratek Pharmaceuticals, INC. | $37.45 | 2025 | Nuzyra |
| Pfizer INC. | $30.16 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.63 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $22.35 | 2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $21.37 | 2024 | |
| Advanced Respiratory, INC | $19.64 | 2019 | |
| Phadia US INC. | $19.33 | 2025 | Immunocap |
| Scilex Pharmaceuticals INC. | $18.53 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.19 | 2025 | Zoryve |
| Jazz Pharmaceuticals INC. | $17.69 | 2019 | |
| Genentech USA, INC. | $17.57 | 2022 | |
| Supernus Pharmaceuticals, INC. | $16.24 | 2025 | Qelbree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.94 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zeba Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.